| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 31 December 2025 |
| for |
| Pharmalys Limited |
| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 31 December 2025 |
| for |
| Pharmalys Limited |
| Pharmalys Limited (Registered number: 06485910) |
| Contents of the Financial Statements |
| for the Year Ended 31 December 2025 |
| Page |
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 4 |
| Pharmalys Limited |
| Company Information |
| for the Year Ended 31 December 2025 |
| DIRECTOR: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| Pharmalys Limited (Registered number: 06485910) |
| Balance Sheet |
| 31 December 2025 |
| 31.12.25 | 31.12.24 |
| as restated |
| Notes | £ | £ | £ | £ |
| FIXED ASSETS |
| Intangible assets | 4 |
| Tangible assets | 5 |
| CURRENT ASSETS |
| Debtors | 6 |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 7 |
| NET CURRENT LIABILITIES | ( |
) | ( |
) |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
) |
( |
) |
| CREDITORS |
| Amounts falling due after more than one year | 8 | ( |
) |
| PROVISIONS FOR LIABILITIES | 10 | ( |
) | ( |
) |
| NET LIABILITIES | ( |
) | ( |
) |
| CAPITAL AND RESERVES |
| Called up share capital | 11 |
| Retained earnings | 12 | ( |
) | (925,009 | ) |
| SHAREHOLDERS' FUNDS | ( |
) | ( |
) |
| The director acknowledges her responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| Pharmalys Limited (Registered number: 06485910) |
| Balance Sheet - continued |
| 31 December 2025 |
| The financial statements were approved by the director and authorised for issue on |
| Pharmalys Limited (Registered number: 06485910) |
| Notes to the Financial Statements |
| for the Year Ended 31 December 2025 |
| 1. | STATUTORY INFORMATION |
| Pharmalys Limited is a |
| The presentation currency of the financial statements is the Pound Sterling (£). |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Going Concern |
| The director monitors the cornpany closely to ensure that the company has adequate funds to enable it to |
| continue in operation as a going concern and meet its liabilities as they fall due for payment. |
| Based on this information, and informal borrowing being made available the director is satisfied that the company have sufficient resources to enable it to continue in existence far the foreseeable future, this being a period of at least twelve months from the date of approval of these financial statements, and that it is therefore appropriate for these financial statements to be prepared on the going concern basis. |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Intangible assets |
| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. |
| Tangible fixed assets |
| Fixtures and fittings | - |
| Computer equipment | - |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Pharmalys Limited (Registered number: 06485910) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2025 |
| 2. | ACCOUNTING POLICIES - continued |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Foreign currencies |
| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result. |
| Hire purchase and leasing commitments |
| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| 4. | INTANGIBLE FIXED ASSETS |
| Computer |
| software |
| £ |
| COST |
| Additions |
| At 31 December 2025 |
| AMORTISATION |
| Amortisation for year |
| At 31 December 2025 |
| NET BOOK VALUE |
| At 31 December 2025 |
| Pharmalys Limited (Registered number: 06485910) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2025 |
| 5. | TANGIBLE FIXED ASSETS |
| Fixtures |
| and | Computer |
| fittings | equipment | Totals |
| £ | £ | £ |
| COST |
| At 1 January 2025 |
| Additions |
| At 31 December 2025 |
| DEPRECIATION |
| At 1 January 2025 |
| Charge for year |
| At 31 December 2025 |
| NET BOOK VALUE |
| At 31 December 2025 |
| At 31 December 2024 |
| 6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 31.12.25 | 31.12.24 |
| as restated |
| £ | £ |
| Trade debtors |
| Other debtors |
| 7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 31.12.25 | 31.12.24 |
| as restated |
| £ | £ |
| Bank loans and overdrafts |
| Trade creditors |
| Taxation and social security |
| Other creditors |
| 8. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |
| 31.12.25 | 31.12.24 |
| as restated |
| £ | £ |
| Bank loans |
| Pharmalys Limited (Registered number: 06485910) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2025 |
| 9. | SECURED DEBTS |
| The following secured debts are included within creditors: |
| 31.12.25 | 31.12.24 |
| as restated |
| £ | £ |
| Bank overdraft |
| Bank loans |
| The aggregate amount of creditors for which security has been given amounted to £4,165 (2024 - £14,166) and is supported by a guarantee from the UK Government to the bank under the Bounce Back Loan Scheme. |
| 10. | PROVISIONS FOR LIABILITIES |
| 31.12.25 | 31.12.24 |
| as restated |
| £ | £ |
| Deferred tax |
| Accelerated capital allowances |
| Deferred |
| tax |
| £ |
| Balance at 1 January 2025 |
| Accelerated capital allowances | (633 | ) |
| Balance at 31 December 2025 |
| 11. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 31.12.25 | 31.12.24 |
| value: | as restated |
| £ | £ |
| Ordinary | £1 | 1 | 1 |
| Pharmalys Limited (Registered number: 06485910) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2025 |
| 12. | RESERVES |
| The financial statements have been restated to correct material errors relating to under-recorded purchases and trade creditors due to an administrative omission of supplier invoices in prior periods. |
| The effect of these corrections has been recognized retrospectively. As a result, purchases and trade creditors were understated by £139,718 in the financial year ended 31 December 2022 and by £271,361 in the financial year ended 31 December 2023. |
| Consequently, the comparative figures for the year ended 31 December 2024 have been restated. The cumulative effect of this restatement is an increase in trade creditors of £411,079 and a corresponding decrease in the opening retained earnings brought forward into 2024 of £411,079. There is no impact on the profit or loss reported for the financial year ended 31 December 2024. |
| 13. | PENSION COMMITMENTS |
| The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £6,037 (2024 - £12,007). Contributions totalling £Nil (2024 - £1,884) were payable to the fund at the balance sheet date. |
| 14. | RELATED PARTY DISCLOSURES |
| At the balance sheet date, the balance due to the director was £132,724 (2024 - £123,925). |